Enhanced response to tolbutamide in uremia

Pitfalls of pharmacokinetic dosage guidelines in renal insufficiency

As the renal elimination of most drugs is closely correlated with the endogenous creatinine clearance, it is possible to use this parameter of kidney function to adjust drug dosage in renal failure. However, this simple procedure neglects possible changes in the volume of distribution, plasma protein binding, drug metabolism, intestinal absorption, and pharmacodynamics in renal insufficiency, as well as the occurrence of biologically active drug metabolites. Because of these uncertainties in critical cases the validity of the dosage calculated using the creatinine clearance should be checked by clinical surveillance and measurements of drug blood concentrations. Further, pharmacokinetic dosage guidelines based on the individual creatinine clearance may not be applicable to diuretics and drugs which have markedly differing kinetics of pharmacodynamic effects and blood levels.

The role of growth hormone in the glucose intolerance of uremia

The fasting plasma growth hormone (GH) concentration and the plasma growth hormone response to sustained hyperglycemia was examined in 8 chronically uremic subjects before and after hemodialysis employing the hyperglycemia clamp technique. The plasma glucose concentration was acutely raised and maintained at +125 mg/100 ml above basal levels. Since the glucose concentration was held constant, the glucose infusion rate is an index of glucose metabolism (M) and M divided by the plasma insulin response (I) is a measure of tissue sensitivity to insulin. Predialysis, the fasting GH concentration, 4.0 +/- 1.0 ng/ml, was significantly greater than controls, 0.3 +/- 0.1 ng/ml (p less than 0.01), and failed to suppress normally following sustained hyperglycemia. Both M, 4.23 +/- 0.36 mg/kg x min, and M/I, 5.05 +/- 0.79 mg/kg x min per microU/ml, were significantly reduced compared to controls (p less than 0.001). There was no correlation between either the fasting GH concentration or the GH response to sustained hyperglycemia and either M or M/I. Following dialysis both M, 6.30 +/- 0.64 mg/kg x min, and M/I, 8.39 +/- 1.06 mg/kg x min per microU/ml, increased (p less than 0.01) without significant change in either the fasting GH level, 4.0 +/- 1.2 ng/ml, or the plasma GH response to hyperglycemia. It is concluded that while deranged GH physiology is a common accompaniment of the uremic state, it is not responsible for the glucose intolerance and tissue insensitivity to insulin observed in uremia.

Pattern of growth hormone response to insulin, arginine and haemodialysis in uraemic children

Plasma growth hormone (GH) concentrations after insulin and arginine stimulation were estimated in 11 dialyzed and 6 non-dialyzed children with chronic renal failure. Twenty healthy children served as controls. Plasma GH peak concentration and estimation of the total area under the plasma GH concentration-time curve by the trapezoidal rule were used to evaluate results. Elevated basal GH levels and an exaggerated response to the stimuli were seen in several of the patients. The causes of the abnormal GH secretion and the role of high GH levels in carbohydrate intolerance are discussed. No consistent pattern was seen in GH secretion during haemodialysis without glucose in the dialysate. In children undergoing haemodialysis with a fluid containing glucose, plasma GH fell considerably.